Pharmacovigilance At Cipla Training Assessment 2016

Reviewed by Editorial Team
The ProProfs editorial team is comprised of experienced subject matter experts. They've collectively created over 10,000 quizzes and lessons, serving over 100 million users. Our team includes in-house content moderators and subject matter experts, as well as a global network of rigorously trained contributors. All adhere to our comprehensive editorial guidelines, ensuring the delivery of high-quality content.
Learn about Our Editorial Process
| By Shareeza
S
Shareeza
Community Contributor
Quizzes Created: 1 | Total Attempts: 410
| Attempts: 410
Quiz Flashcard
SettingsSettings
Please wait...
  • 1/5 Questions

    Pharmacovigilance activities, if not conducted in line with regulatory requirements can lead to product withdrawal.

    • True
    • False
Please wait...
About This Quiz

This Pharmacovigilance at Cipla Training Assessment 2016 evaluates the understanding of adverse event detection, reporting timelines, and compliance with drug safety regulations. It is crucial for ensuring patient safety and adherence to pharmaceutical standards.

Training Quizzes & Trivia

Quiz Preview

  • 2. 

    The science related to detection, monitoring and prevention of______________ is termed as Pharmacovigilance.

    • All Complaints received on medicines

    • Adverse events

    • Diseases

    • Product Quality Complaints

    Correct Answer
    A. Adverse events
    Explanation
    Pharmacovigilance is the science related to the detection, monitoring, and prevention of adverse events. Adverse events refer to any negative or unexpected reactions or side effects that occur after the administration of a medicine or drug. Pharmacovigilance aims to collect and analyze data on adverse events to ensure the safety and effectiveness of medications, and to take necessary actions such as updating product labels or withdrawing drugs from the market if necessary.

    Rate this question:

  • 3. 

    Your friend mentions to you that her doctor has prescribed Ginette for treatment of hair loss, even though you are aware that this is not an approved indication/use of the drug. According to your friend's HCP, several patients have seen great results and she is optimistic about the treatment. Do you have to report this?

    • No, you do not need to forward a report since the Health Care Professional has written a script for the patient.

    • No, it is not required to forward a report as it is not part of your obligation.

    • Yes, Forward a product safety report of this off-label use.

    • No safety report is required because there were no unexpected adverse events.

    Correct Answer
    A. Yes, Forward a product safety report of this off-label use.
    Explanation
    The correct answer is to forward a product safety report of this off-label use. Off-label use refers to the use of a medication for a purpose that is not approved by regulatory authorities. Reporting this off-label use is important to ensure that any potential adverse events or side effects are monitored and documented. It is necessary to gather data on the safety and efficacy of medications used in off-label indications to inform future prescribing practices and patient safety.

    Rate this question:

  • 4. 

    All Adverse Events on Cipla products should be emailed to:​

    Correct Answer
    Explanation
    The correct answer is [email protected]. This email address is specifically designated for reporting adverse events related to Cipla products. It is likely monitored by the drug safety team at Cipla, who are responsible for collecting and analyzing information on any negative effects or side effects experienced by patients using their products. By emailing adverse events to this address, individuals can ensure that their reports are being sent to the appropriate department for review and action.

    Rate this question:

  • 5. 

    A patient informs you about having an allergy when she started a Cipla drug, within what time frame should you forward a report the Cipla SA, Drug Safety Unit?

    • Within 1 business day, or 3 calendar days (whichever is earlier) of when you read the information

    • Within 1 business day, or 3 calendar days (whichever is earlier) from when the information is first received

    • Within 48 hours of your awareness

    • No safety report is required because the AE is mentioned in the Product label

    Correct Answer
    A. Within 1 business day, or 3 calendar days (whichever is earlier) from when the information is first received
    Explanation
    The correct answer is Within 1 business day, or 3 calendar days (whichever is earlier) from when the information is first received. This means that as soon as the patient informs you about their allergy to the Cipla drug, you should forward a report to the Cipla SA Drug Safety Unit within 1 business day or 3 calendar days, whichever comes earlier. It emphasizes the importance of timely reporting and ensures that the necessary actions can be taken promptly to address any potential safety concerns.

    Rate this question:

Quiz Review Timeline (Updated): Mar 22, 2023 +

Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.

  • Current Version
  • Mar 22, 2023
    Quiz Edited by
    ProProfs Editorial Team
  • Jun 07, 2016
    Quiz Created by
    Shareeza
Back to Top Back to top
Advertisement
×

Wait!
Here's an interesting quiz for you.

We have other quizzes matching your interest.